Speaker
Event Date & Time
Date: February 18, 2025
Time: 8am PDT, 5pm CET
Abstract
Join us for an enlightening webinar with Dr. Bruno Paiva, where we will delve into the Next Generation Flow™ Technology. This technology, known for its high sensitivity and standardized procedures, is a powerful tool for detecting minimal residual disease (MRD) in Multiple Myeloma. Dr. Paiva will explain the criteria set by the International Myeloma Working Group (IMWG) for MRD negativity, helping you understand its importance in interpreting clinical trial results and in routine practice. He will also demonstrate how Next Generation Flow shows high concordance in detecting MRD compared to other techniques and share his insights on the FDA/ODAC hearing regarding the MRD negative CR endpoint. A key highlight of this webinar will be the discussion on the reproducibility of results between clinical trials and routine practice, bridging the gap between research and real-world application. Don't miss this opportunity to learn from one of the leading experts in the field. Register now to secure your spot and stay at the forefront of clinical research and patient care.
Learning Objectives
- Understand the Next Generation Flow™ technology: Learn about its high sensitivity and standardized procedures for detecting minimal residual disease (MRD) in Multiple Myeloma.
- Interpret MRD negativity criteria: Gain insights into the criteria set by the International Myeloma Working Group (IMWG) for MRD negativity and its significance in clinical trial results and routine practice.
- Evaluate reproducibility of MRD detection: Explore the reproducibility of MRD detection results between clinical trials and routine practice, and understand the high concordance of Next Generation Flow compared to other techniques.
Webinars will be available for unlimited on-demand viewing after live event.
You May Also Like
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
FEB 25, 2025 | 1:00 PM
Quality efforts in the clinical laboratory are always under the microscope- a hyper-focus for laboratorians from start to finish. Recognizing the external factors that affect hemostasis test...
Loading Comments...